TY - JOUR
T1 - Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty
AU - Okamura, Atsunori
AU - Ohishi, Mitsuru
AU - Rakugi, Hiromi
AU - Katsuya, Tomohiro
AU - Yanagitani, Yoshihiro
AU - Takiuchi, Shin
AU - Taniyama, Yoshiaki
AU - Moriguchi, Koichi
AU - Ito, Hiroshi
AU - Higashino, Yorihiko
AU - Fujii, Kenshi
AU - Higaki, Jitsuo
AU - Ogihara, Toshio
PY - 1999/10
Y1 - 1999/10
N2 - Angiotensin-converting enzyme (ACE) inhibitors are reported to prevent neointimal formation after balloon injury in animal models, but in most prospective studies in humans, ACE inhibitors failed to prevent restenosis after percutaneous transluminal coronary angioplasty (PTCA). The ACE genotype assigned by an insertion/deletion (I/D) polymorphism is known to affect the potency of ACE inhibitors in several renal diseases. The authors attempted to clarify whether the effect of ACE inhibitors on restenosis might be modified by the ACE genotype. A total of 126 patients was randomly and prospectively assigned to the control group and the imidapril group. In the imidapril group, patients received 5 mg imidapril daily, starting 1 day before PTCA and continuing for 3 to 6 months. Forty-six control (65 vessels) and 32 imidapril patients (43 vessels) completed the study. The minimal lumen diameter before and after the procedure did not differ significantly among the groups with the three genotypes (II, ID, and DD) in both the control and imidapril groups. Late luminal loss during the follow-up period was not related to the ACE genotype in the control group but was significantly related in the imidapril group (II, 0.63 ± 0.19 mm; ID + DD, 1.12 ± 0.14 mm, p < 0.05). Furthermore, in the II genotype, imidapril significantly reduced late loss and restenosis rate as defined by most of the frequently used definitions. In conclusion the ACE I/D polymorphism may influence the effect of ACE inhibitors in preventing restenosis after PTCA.
AB - Angiotensin-converting enzyme (ACE) inhibitors are reported to prevent neointimal formation after balloon injury in animal models, but in most prospective studies in humans, ACE inhibitors failed to prevent restenosis after percutaneous transluminal coronary angioplasty (PTCA). The ACE genotype assigned by an insertion/deletion (I/D) polymorphism is known to affect the potency of ACE inhibitors in several renal diseases. The authors attempted to clarify whether the effect of ACE inhibitors on restenosis might be modified by the ACE genotype. A total of 126 patients was randomly and prospectively assigned to the control group and the imidapril group. In the imidapril group, patients received 5 mg imidapril daily, starting 1 day before PTCA and continuing for 3 to 6 months. Forty-six control (65 vessels) and 32 imidapril patients (43 vessels) completed the study. The minimal lumen diameter before and after the procedure did not differ significantly among the groups with the three genotypes (II, ID, and DD) in both the control and imidapril groups. Late luminal loss during the follow-up period was not related to the ACE genotype in the control group but was significantly related in the imidapril group (II, 0.63 ± 0.19 mm; ID + DD, 1.12 ± 0.14 mm, p < 0.05). Furthermore, in the II genotype, imidapril significantly reduced late loss and restenosis rate as defined by most of the frequently used definitions. In conclusion the ACE I/D polymorphism may influence the effect of ACE inhibitors in preventing restenosis after PTCA.
UR - http://www.scopus.com/inward/record.url?scp=0032852126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032852126&partnerID=8YFLogxK
U2 - 10.1177/000331979905001005
DO - 10.1177/000331979905001005
M3 - Article
C2 - 10535720
AN - SCOPUS:0032852126
VL - 50
SP - 811
EP - 822
JO - Angiology
JF - Angiology
SN - 0003-3197
IS - 10
ER -